Norcantharidin is the demethylated form of Cantharidin, which is the active ingredient of the blister beetle, Mylabris, a long used Chinese traditional medicine. Though not well publicised outside China, Norcantharidin is known to possess significant anti-hepatoma activity, and is relatively free from side effects. In the present study, glucose oxidation in tumour and liver tissue slices harvested from hepatomabearing animals was quantified by measuring the radioactivity of 14C-labelled CO released from 14C-glucose in oxygen-enriched incubation medium. Results were expressed asa tumour/liver ratio. For comparison, treatments with Norcantharidin, Adriamycin and with hepatic artery ligation were studied. The mean tumour/liver ratio was 4.2+2.2 in untreated controls, but dropped significantly to 2.3+0.5 (p<0.05) with intra-arterial Norcantharidin (0.5 mg/kg) and to 2.3+0.7 (p<0.05) with intra-arterial Adriamycin (2.4 mg/kg), and to 2.2+0.7 (p<0.05) with hepatic artery ligation. However, with intravenous Adriamycin at 2.4 mg/kg, the mean tumour/liver ratio was reduced to only 3.5+2.0 and was not significantly different from untreated controls. It is concluded that intra-arterial Norcantharidin is as effective as intraarterial Adriamycin and hepatic artery ligation in suppressing tumour glucose oxidative metabolism. These results imply that Norcantharidin may have a role to play in the chemotherapy ofprimary liver cancer.
INTRODUCTION
As searches are underway for new anti-cancer drugs, old drugs are being looked at as novel options to be given by various routes of administration. Although Mylabris, the dried body of the Chinese blister beetle, has been used as a traditional medicine in China for more than two thousand years, recent attention is being focused on its anti-cancer properties1. The earliest record of Mylabris as a medicine can be tracked back to 300-168 B.C. in China, and later in a medical monograph, Materia Medica published .in about A.D.77 in Europe2. The active constituent of Mylabris has been identified as Cantharidin which possesses not only anti-cancer activity but also causes leukocytosis and haemorrhagic cystitis. Adriamycin were similarly given. The patency of the hepatic artery one hour after intra-arterial drug administration was confirmed by the presence of pulsations observable under the operating microscope, and all animals were then sacrificed.
(2) Femoral vein cannulation A groin incision was made in the anaesthetised rat, following which the common femoral vein was exposed. Under In addition to the above, separate liver and tumour specimens approximately 400-500 mg in wet weight were harvested from the sacrificed animal and dried in a hot air oven at 45C for 3 weeks to obtain the wet wt/ dry wt ratio. The results of tumour oxidation of either the tumour or normal liver tissue were then expressed as dpm/mg dry weight.
Experimental Design
The study was conducted in two parts: Experiment 1 In the first experiment, 14 rats were used and of these 6 were tumour-bearing animals and 8 were tumourfree animals. A lapse of 3 weeks following tumour cell transplantation was allowed in the tumour-bearing animals on purpose, in order to obtain advanced turnouts of sizes up to [8] [9] [10] [11] [12] Forty-one tumour-bearing rats were used in this experiment and all animals had small-sized hepatomas.
A lapse of 10-14 days after tumour cell inoculation in the animals was allowed so that the tumour sizes at the time of experiment were each approximately 1-2 cm3. in volume. The objective ofusing small tumours in this study design was two-fold. Firstly, the associated operative difficulties of performing hepatic artery ligation and gastroduodenal artery cannulation in the presence of bulky liver tumour could be avoided. Secondly, the design permits a comparison between the tumour/liver ratio of glucose oxidation of small tumours in this group against that of large advanced tumours in the Experiment 1.
The 41 tumour-bearing animals in this experiment were assigned to 5 groups as follows:
(1) Control group (n=9), in which no treatment was given.
(2) Intravenous Adriamycin group (n=7), in which Adriamycin was infused as a single dose of 2.4 mg/kg in 0.3 ml saline over 5 minutes through the femoral vein, followed by flushing with 0.5 ml of saline. (5) Hepatic artery ligation group (n=8), in which all animals had their proper hepatic artery ligated in the manner described above.
All animals in the control group were sacrificed untreated whereas those in the other four treated groups were sacrificed one hour after institution of treatment. Tisssue specimens were separately harvested from the hepatoma and adjacent normal liver tissue and were assayed for their glucose oxidation capacity. The results of glucose oxidation of the hepatoma tisssue and of the normal liver tissue in each animal was subsequently expressed as "tumour/liver ratio" in that particular animal. the tumour-bearing animals. They were not significantly different from one another. The hepatoma tissue in the tumour-bearing rats however showed a glucose oxidation of 763.6+ 167 dpm/mg dry wt. and was markedly higher than their corresponding normal liver tissue (p<0.01) (Fig. 2) It has been previously shown that a growing malignant tumour behaves as a trap for glucose and acts as a powerful hypoglycaemic factor imposing a strain on the host to maintain glucose homeostasis17. The liver tissue of the tumour-bearing host, which is the site for glucostatic functions, might be expected to mainfest disturbances in glucose metabolism. However, no differences in glucose oxidation have been observed between the liver tissue of tumour-free and that of tumour-bearing rats in this study.
Following tumour treatment with intraarterial Norcantharidin, the tumour/liver ratio was nearly halved at the end of the first hour. A similar effect was also observed when the tumour was treated with intra-arterial Adriamycin, indicating that both drugs, when given by the arterial route, exhibit a similar potency. When the same dosage of Adriamycin was given by the intravenous route, the depression in tumour metabolism was significantly less. This can be explained by the fact that the concentration of drug delivered by the intravenous route to the turnout site is significantly less when compared to that delivered by the arterial route TM. In one study, when the hepatic venous drug concentrations were compared between administration by the intra-venous and the intra-arterial routes, up to fivefold higher concentration is found when given by the hepatic artery route9.
The results ofthe present study concurs with current clinical recommendations that chemotherapy for primary liver cancer, if indicated, should preferably be administered by the arterial route2. The results of intravenous Adriamycin, even though it does not contribute to the comparative assessment ofthe efficacy of intra-arterial Norcantharidin, has nonetheless been included in this study mainly because, it remains a treatment modality that is commonly used clinically for irresectable hepatoma. The message must be reinforced to the clinical oncologist that the intravenous route should, whenever feasible, be discarded in favour ofthe intra-arterial route in the administration of chemotherapy for primary liver cancer.
It is known that the blood flow to liver tumours are predominantly supplied by the arterial route 2,2 and it has been shown that ligation of hepatic artery could inhibit liver tumour growth3'24'25, at least in the initial stages before collaterals developed6. It is presumed that the inhibition in tumour growth by ischae mia is mediated through suppression of tumour metabolism. Since hepatic artery ligation is clinically an effective, though temporary, method of treating irresectable liver tumours that yields consistent results, its inclusion as a study group for comparison has provided a good yardstick on which to evaluate the efficacy of all other forms of treatment. Hepatic artery ligation has been shown to lower the hepatoma glucose oxidation capacity by as much as 48% after one hour in this study. By comparison, only a 25% reduction in glucose oxidation was achievable after one hour following hepatic artery ligation in a metastatic liver adenocarcinoma model in a similar previous study1.
In conclusion, Norcantharidin is attracting interest from clinicians because of its anti-hepatoma properties. When given by the intra-arterial route, it is as effective as intra-arterial Adriamycin andhepatic artery ligation in the suppression of tumour oxidative glucose metabolism in a hepatocellular carcinoma model in the rat. As this drug has minimal side effects and does not cause bone marrow suppression, it has an edge over Adriamycin and may potentially establish a place in the chemotherapy of primary liver cancer in future.
